TrialJournal of the Pediatric Infectious Diseases Society2015

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

Sharon Nachman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.